Biomarkers for Monitoring of Changes in Disease Activity in Ulcerative Colitis
BACKGROUND: In recent years, various biomarkers of ulcerative colitis (UC) have emerged; however, few studies have simultaneously examined the utility of multiple biomarkers for monitoring disease activity. Additionally, serum leucine-rich alpha-2 glycoprotein (LRG), a new biomarker, may show a blunt response to anti-TNF antibody therapy. This prospective study explored effective biomarkers that could monitor disease activity changes in patients with UC. In addition, we examined the effect of anti-TNF antibody therapy on changes in LRG.
METHODS: Blood and stool samples were collected twice from patients with UC: at baseline and at least 8 weeks later. Changes in serum LRG, interleukin (IL)-6, prealbumin (pre-Alb), high-sensitivity C-reactive protein (hs-CRP), CRP, and fecal calprotectin (FC) were measured and correlated with changes in disease activity. The relationship between anti-TNF antibody therapy and LRG levels was also examined in patients with the same disease activity.
RESULTS: Forty-eight patients with UC (96 samples) were analyzed. ΔLRG and ΔIL-6 correlated strongly with the change in the partial Mayo (pMayo) score between the two time points (ΔpMayo) (r = 0.686, 0.635, respectively). In contrast, FC and IL-6 were particularly accurate predictors of clinical remission, and their area under the curves (AUCs) were significantly higher than that of CRP (AUC: 0.81, 0.76 vs. 0.50; p = 0.001, 0.005). No association was found between the administration of anti-TNF antibody preparations and the LRG values.
CONCLUSIONS: Correlations were found between changes in UC disease activity and LRG, IL-6, pre-Alb, hs-CRP, CRP, and FC. LRG reflects disease activity during anti-TNF antibody therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Journal of clinical medicine - 12(2023), 22 vom: 18. Nov. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tatsumi, Yoshihiro [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-TNF antibody therapy |
|---|
| Anmerkungen: |
Date Revised 27.11.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/jcm12227165 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364939958 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364939958 | ||
| 003 | DE-627 | ||
| 005 | 20231226100623.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/jcm12227165 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1216.xml |
| 035 | |a (DE-627)NLM364939958 | ||
| 035 | |a (NLM)38002777 | ||
| 035 | |a (PII)7165 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tatsumi, Yoshihiro |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Biomarkers for Monitoring of Changes in Disease Activity in Ulcerative Colitis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 27.11.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a BACKGROUND: In recent years, various biomarkers of ulcerative colitis (UC) have emerged; however, few studies have simultaneously examined the utility of multiple biomarkers for monitoring disease activity. Additionally, serum leucine-rich alpha-2 glycoprotein (LRG), a new biomarker, may show a blunt response to anti-TNF antibody therapy. This prospective study explored effective biomarkers that could monitor disease activity changes in patients with UC. In addition, we examined the effect of anti-TNF antibody therapy on changes in LRG | ||
| 520 | |a METHODS: Blood and stool samples were collected twice from patients with UC: at baseline and at least 8 weeks later. Changes in serum LRG, interleukin (IL)-6, prealbumin (pre-Alb), high-sensitivity C-reactive protein (hs-CRP), CRP, and fecal calprotectin (FC) were measured and correlated with changes in disease activity. The relationship between anti-TNF antibody therapy and LRG levels was also examined in patients with the same disease activity | ||
| 520 | |a RESULTS: Forty-eight patients with UC (96 samples) were analyzed. ΔLRG and ΔIL-6 correlated strongly with the change in the partial Mayo (pMayo) score between the two time points (ΔpMayo) (r = 0.686, 0.635, respectively). In contrast, FC and IL-6 were particularly accurate predictors of clinical remission, and their area under the curves (AUCs) were significantly higher than that of CRP (AUC: 0.81, 0.76 vs. 0.50; p = 0.001, 0.005). No association was found between the administration of anti-TNF antibody preparations and the LRG values | ||
| 520 | |a CONCLUSIONS: Correlations were found between changes in UC disease activity and LRG, IL-6, pre-Alb, hs-CRP, CRP, and FC. LRG reflects disease activity during anti-TNF antibody therapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a LRG (leucine-rich alpha-2-glycoprotein) | |
| 650 | 4 | |a anti-TNF antibody therapy | |
| 650 | 4 | |a biomarkers | |
| 650 | 4 | |a fecal calprotectin | |
| 650 | 4 | |a ulcerative colitis | |
| 700 | 1 | |a Kakimoto, Kazuki |e verfasserin |4 aut | |
| 700 | 1 | |a Hara, Azusa |e verfasserin |4 aut | |
| 700 | 1 | |a Mizuta, Noboru |e verfasserin |4 aut | |
| 700 | 1 | |a Numa, Keijiro |e verfasserin |4 aut | |
| 700 | 1 | |a Kinoshita, Naohiko |e verfasserin |4 aut | |
| 700 | 1 | |a Nakazawa, Kei |e verfasserin |4 aut | |
| 700 | 1 | |a Koshiba, Ryoji |e verfasserin |4 aut | |
| 700 | 1 | |a Hirata, Yuki |e verfasserin |4 aut | |
| 700 | 1 | |a Ota, Kazuhiro |e verfasserin |4 aut | |
| 700 | 1 | |a Miyazaki, Takako |e verfasserin |4 aut | |
| 700 | 1 | |a Nakamura, Shiro |e verfasserin |4 aut | |
| 700 | 1 | |a Sakagami, Kayoko |e verfasserin |4 aut | |
| 700 | 1 | |a Arimitsu, Shoko |e verfasserin |4 aut | |
| 700 | 1 | |a Ito, Hiroaki |e verfasserin |4 aut | |
| 700 | 1 | |a Nishikawa, Hiroki |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical medicine |d 2012 |g 12(2023), 22 vom: 18. Nov. |w (DE-627)NLM230666310 |x 2077-0383 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2023 |g number:22 |g day:18 |g month:11 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/jcm12227165 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2023 |e 22 |b 18 |c 11 | ||